Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies
US10081680B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 11, 2015 |
| Grant date | Sep 25, 2018 |
| Priority date | — |
| Expiry date | Mar 11, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70503
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Anti-SIRPα antibodies, including multi-specific anti-SIRPα antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRPα and can block the interaction of CD47 on one cell with SIRPα on a phagocytic cell. Antibodies that are bispecific for SIRPα and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti-SIRPα antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRPα antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRPα antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.